ストックスクリーナーアプリを入手
0.5968
14.06%
-0.0976
前日終値:
$0.6944
開ける：
$0.677
24時間の取引高:
2.65M
Relative Volume:
22.20
時価総額：
$2.93M
収益：
$29.57M
当期純損益:
$-34.68M
株価収益率:
-0.000842
EPS:
-708.7214
ネットキャッシュフロー:
$-7.58M
1週間 パフォーマンス:
-26.31%
1か月 パフォーマンス:
-40.32%
6か月 パフォーマンス:
-97.40%
1年 パフォーマンス:
-98.86%
1日の値動き範囲:
$0.5716
$0.6808
1週間の範囲:
$0.5716
$0.825
52週間の値動き範囲:
$0.5716
$77.63
Jaguar Health Inc Stock (JAGX) Company Profile
名前
Jaguar Health Inc
セクター
電話
415-371-8300
住所
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.5968 | 4.29M | 29.57M | -34.68M | -7.58M | -708.72 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 開始されました | Rodman & Renshaw | Buy |
Jaguar Health Inc (JAGX) 最新ニュース
Form 424B3 Jaguar Health, Inc. - StreetInsider
Jaguar Health | 424B3: Prospectus - Moomoo
Jaguar Health revenue falls 59% to $1.2 million - grafa.com
Jaguar Health | 10-Q: Quarterly report - Moomoo
Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and Strategic Pivot - GuruFocus
Jaguar Health (JAGX) Shifts Focus to Rare GI Treatments Amid Cha - GuruFocus
Jaguar Health presents crofelemer data at ESPGHAN 2026 - scanx.trade
Jaguar Health Sets Q2 2027 NDA Submission Timeline for MVID Treatment - Minichart
Jaguar Health Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Jaguar Health Posts Q2 Total Revenue $1.2 Million, EPS $-15.68 - TradingView
Jaguar Health Q2 loss narrows 96% as revenue falls 59% on licensing shift - scanx.trade
Q2 2026 Jaguar Health Inc Earnings Call Transcript - GuruFocus
Jaguar Health Reports $1.2 Million Q2 Revenue and $12.7 Million Net Loss - Quiver Quantitative
Jaguar Health Reports Second Quarter 2026 Financials - ACCESS Newswire
Jaguar Health to hold Q2 2026 investor webcast on August 19 - scanx.trade
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates - Yahoo Finance
JAGX Q2'26 Earnings: EPS estimate is (52.15) USD - TradingView
Jaguar Health, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Jaguar Health Delays Quarterly SEC Filing - TipRanks
Jaguar Health (JAGX) cites major subsequent events in delaying Q2 2026 10-Q - Stock Titan
Jaguar Health (JAGX) details 40.9M-share resale tied to $40M equity line - Stock Titan
Jaguar Health (JAGX) Ticks Up 2.22% to $0.96, Approaching Key Resistance at $1.01Analyst Downgrade Signals - dars.gov.et
Jaguar Health (JAGX) Secures $2 Million Holdback Payment from Fu - GuruFocus
Why is Jaguar Health stock gaining today? - Investing.com
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 - ACCESS Newswire
News by ACCESS Newswire on TradingView, 2026-08-05 - TradingView
After 12 Months, Crofelemer Cut Support Up to 48% in One MVID Patient - Stock Titan
Why is Jaguar Health stock gaining today? By Investing.com - Investing.com Australia
Jaguar Health (JAGX) Consolidates at $1.0: Support and Resistance Define Trading RangeMcClellan Summation - dars.gov.et
Jaguar Health (JAGX) Holds at $1.00 as Tight Trading Range Defines Key Levels to WatchInstitutional Buy Signals - Vinanet
Jaguar Health (JAGX) Dips 3.56% to $1.00, Pressing Key Support LevelSector Neutral Pair - Vinanet
Jaguar Health (JAGX) Highlights Market Potential of Neonorm Dog Amidst Challenging Valuation - GuruFocus
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog - Yahoo! Finance Canada
Jaguar Health finds strong market interest in N... - Pluang
Jaguar Health Inc (JAGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jaguar Health Inc (JAGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jaguar Health, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) - ACCESS Newswire
TradingKey - TradingKey
Jaguar Health Inc. (JAGX) Q1 2026 Earnings: Significant Earnings Miss Amid Absent RevenueConsensus Miss Rate - dars.gov.et
Jaguar Health (NASDAQ: JAGX) puts major dilution and incentive plan votes to investors - Stock Titan
JAGX Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Revenue Not ReportedDividend Increase Stocks - Vinanet
Jaguar Health (JAGX) Secures Compassionate Use for Crofelemer in EU - GuruFocus
Jaguar Reports Up to 48% Lower Weekly Support in One MVID Patient - Stock Titan
Jaguar Health (JAGX) Registration filing Summary - Quartr
Jaguar Health (JAGX) Holds at $1.30 as Support Test Looms – What’s Next?Vanna Flow - dars.gov.et
Jaguar Health Company Profile & Introduction - Moomoo
JAGUAR HEALTH INC (JAGX) Stock Chart - ChartMill
Form S-1 Jaguar Health Inc For: 16 July By Investing.com - Investing.com South Africa
Enterprise value to EBIT forward of Jaguar Health, Inc. – FWB:1JA1 - TradingView
Jaguar Health (NASDAQ: JAGX) plans 5.5M-share resale registration - Stock Titan
Jaguar Health Inc (JAGX) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):